检索结果-南通市图书馆

CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells

Signal Transduction and Targeted Therapy 2021年第1期6卷 95-104页

作者： Ke wang wei Chen Zheng Zhang yongqiang Deng Jian-qi Lian Peng Du Ding wei Yang Zhang Xiu-Xuan Sun Li Gong Xu Yang Lei He Lei Zhang Zhiwei Yang Jie-Jie Geng Ruo Chen Hai Zhang Bin wang Yu-Meng zhu Gang Nan Jian-Li Jiang Ling Li Jiao wu Peng Lin Wan Huang Liangzhi Xie Zhao-Hui Zheng Kui Zhang Jin-Lin Miao Hong-yong Cui Min Huang jun Zhang Ling Fu Xiang-Min Yang Zhongpeng Zhao Shihui Sun Hongjing Gu Zhe wang Chun-Fu wang Yacheng Lu ying-ying Liu qing-yi wang Huijie Bian Ping zhuZhi-Nan Chen National Translational Science Center for Molecular Medicine&Department of Cell Biology Fourth Military Medical UniversityXi’an 710032China Beijing Institute of Biotechnology Beijing 100071China State Key Laboratory of Pathogen and Biosecurity Beijing Institute of Microbiology and EpidemiologyBeijing 100071China Tangdu Hospital Fourth Military Medical UniversityXi’an 710038China MOE Key Laboratory for Nonequilibrium Synthesis and Modulation of Condensed Matter Xi’an Jiaotong UniversityXi’an 710049China Sino Biological Inc. Beijing 100176China Department of Clinical Immunology Xijing HospitalFourth Military Medical UniversityXi’an 710032China School of Basic Medicine Fourth Military Medical UniversityXi’an 710032China

In face of the everlasting battle toward COVID-19 and the rapid evolution of SARS-CoV-2,no specific and effective drugs for treating this disease have been reported until ***-converting enzyme 2(ACE2),a receptor of SARS-CoV-2,mediates the virus infection by binding to spike *** ACE2 is expressed in the lung,kidney,and intestine,its expressing levels are rather low,especially in the *** the great infectivity of COVID-19,we speculate that SARS-CoV-2 may depend on other routes to facilitate its ***,we first discover an interaction between host cell receptor CD147 and SARS-CoV-2 spike *** loss of CD147 or blocking CD147 in Vero E6 and BEAS-2B cell lines by anti-CD147 antibody,Meplazumab,inhibits SARSCoV-2 *** of human CD147 allows virus entry into non-susceptible BHK-21 cells,which can be neutralized by CD147 extracellular *** loads are detectable in the lungs of human CD147(hCD147)mice infected with SARS-CoV-2,but not in those of virus-infected wild type ***,virions are observed in lymphocytes of lung tissue from a COVID-19 *** T cells with a property of ACE2 natural deficiency can be infected with SARS-CoV-2 pseudovirus in a dosedependent manner,which is specifically inhibited by ***,CD147 mediates virus entering host cells by ***,our study reveals a novel virus entry route,CD147-spike protein,which provides an important target for developing specific and effective drug against COVID-19.

关键词： ACE2 CD147 intestine

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Prognostic significance of regional lymphadenectomy in T1b gallbladder cancer:Results from 24 hospitals in China

引用

World Journal of Gastrointestinal Surgery 2021年第2期13卷 176-186页

作者： Tai Ren yong-Sheng Li Xue-yi Dang Yang Li Zi-Yu Shao Run-Fa Bao yi-jun Shu Xu-An wang Wen-Guang wu Xiang-Song wu Mao-Lan Li Hong Cao Kun-Hua wang Hong-Yu Cai Chong Jin Hui-Han Jin Bo Yang Xiao-qing Jiang Jian-feng Gu Yun-Fu Cui Zai-Yang Zhang Chun-Fu zhu Bei Sun Chao-Liu Dai Lin-Hui Zheng Jing-Yu Cao Zhe-wei Fei Chang-jun Liu Bing Li jun Liu Ye-Ben qian yi wang Ya-wei Hua Xi Zhang Chang Liu Wan-Yee Lau ying-Bin Liu Department of General Surgery Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai 200092China Shanghai Key Laboratory of Biliary Tract Disease Research Shanghai 200092China Department of Biliary-Pancreatic Surgery Renji Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai 200127China State Key Laboratory for Oncogenes and Related Genes Shanghai 200127China Department of General Surgery Shanxi Provincial Cancer HospitalTaiyuan 030013Shanxi ProvinceChina Department of GI Surgery China-Japan Union Hospital of Jilin UniversityChangchun 130033Jilin ProvinceChina Department of Gastrointestinal and Hernia Surgery The First Affiliated Hospital of Kunming Medical UniversityKunming 650031Yunnan ProvinceChina Department of Hepatobiliary Surgery Nantong Tumor HospitalNantong 226361Jiangsu ProvinceChina Department of General Surgery Taizhou Municipal HospitalTaizhou 318000Jiangsu ProvinceChina Department of Hepatobiliary Surgery Wuxi Second People's HospitalWuxi 214002Jiangsu ProvinceChina Department of General Surgery The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou 325015Zhejiang ProvinceChina Department of Biliary Tract Surgery Second Military Medical UniversitySecondary Military Medical UniversityShanghai 200438China Department of General Surgery Changshu No.1 People’s Hospital Affiliated to Soochow UniversityChangshu 215500Jiangsu ProvinceChina Department of Hepatopancreatobiliary Surgery Second Affiliated Hospital of Harbin Medical UniversityHarbin 150086Heilongjiang ProvinceChina Department of General Surgery Shaoxing Second HospitalShaoxing 312000Zhejiang ProvinceChina Department of HPB Surgery Changzhou No.2 People’s HospitalChangzhou 213003Jiangsu ProvinceChina Department of Pancreatic and Biliary Surgery The First Affiliated Hospital of Harbin Medical UniversityHarbin 150009Heilongjiang ProvinceChina Department of Hepatobiliary Surgery Shengjing Hospital of China Medical UniversityShenyang 1

BACKGROUND Whether regional lymphadenectomy(RL)should be routinely performed in patients with T1b gallbladder cancer(GBC)remains a subject of *** To investigate whether RL can improve the prognosis of patients with T1b *** We studied a multicenter cohort of patients with T1b GBC who underwent surgery between 2008 and 2016 at 24 hospitals in 13 provinces in *** logrank test and Cox proportional hazards model were used to compare the overall survival(OS)of patients who underwent cholecystectomy(Ch)+RL and those who underwent Ch *** investigate whether combined hepatectomy(Hep)improved OS in T1b patients,we studied patients who underwent Ch+RL to compare the OS of patients who underwent combined Hep and patients who did *** Of the 121 patients(aged 61.9±10.1 years),77(63.6%)underwent Ch+RL,and 44(36.4%)underwent Ch ***(9.1%)patients in the Ch+RL group had lymph node *** 5-year OS rate was significantly higher in the Ch+RL group than in the Ch group(76.3%vs 56.8%,P=0.036).Multivariate analysis showed that Ch+RL was significantly associated with improved OS(hazard ratio:0.51;95%confidence interval:0.26-0.99).Among the 77 patients who underwent Ch+RL,no survival improvement was found in patients who underwent combined Hep(5-year OS rate:79.5%for combined Hep and 76.1%for no Hep;P=0.50).CONCLUSION T1b GBC patients who underwent Ch+RL had a better prognosis than those who underwent ***+Ch showed no improvement in prognosis in T1b GBC *** recommended by both the National Comprehensive Cancer Network and Chinese Medical Association guidelines,RL was only performed in 63.6%of T1b GBC *** Ch+RL should be advised in T1b GBC.

关键词： Gallbladder cancer Lymphadenectomy Hepatectomy Staging Prognosis Surgery

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1:interim analysis of the randomized,controlled,phase 3,non-inferiority TALENT study

引用

Chinese Medical Journal 2020年第24期133卷 2919-2927页

作者： Bin Su Cheng Yao qing-Xia Zhao wei-Ping Cai Min wang Hong-Zhou Lu Yuan-Yuan Chen Li Liu Hui wang Yun He Yu-Huang Zheng Ling-Hua Li Jin-feng Chen Jian-Hua Yu Biao zhu Min Zhao yong-Tao Sun Wen-Hui Lun wei Xia Li-jun Sun Li-Li Dai Tai-yi Jiang Mei-Xia wang qing-Shan Zheng Hai-Yan Peng Yao wang Rong-Jian Lu Jian-Hua Hu Hui Xing yi-Ming Shao Dong Xie Tong Zhang Fu-Jie Zhang Hao wu TALENT Study Team Center for Infectious Diseases Beijing Youan HospitalCapital Medical UniversityBeijing 100069China Frontier Biotechnologies Inc. NanjingJiangsu 211122China Department of Infectious Diseases Infectious Disease Hospital of Henan ProvinceZhengzhouHenan 450061China Infectious Disease Center Guangzhou Eighth People’s HospitalGuangzhou Medical UniversityGuangzhouGuangdong 510060China Institute of HIV/AIDS The First Hospital of ChangshaChangshaHunan 410005China Department of Infectious Diseases Shanghai Public Health Clinical CenterFudan UniversityShanghai 201508China Department of Infectious Diseases National Clinical Center for Infectious DiseasesShenzhen Third People’s HospitalShenzhenGuangdong 518112China Department of Infectious Diseases The Second Xiangya HospitalCentral South UniversityChangshaHunan 410011China Department of Infectious Diseases Xixi Hospital of HangzhouHangzhouZhejiang 310023China State Key Laboratory for Diagnosis and Treatment of Infectious Diseases National Clinical Research Center for Infectious DiseasesThe First Affiliated HospitalZhejiang UniversityHangzhouZhejiang 310003China National Clinical Research Center for Infectious Diseases the Fifth Medical Center of PLA General HospitalBeijing 100039China Department of Infectious Diseases Tangdu HospitalThe Fourth Military Medical UniversityXi’anShaanxi 710038China Clinical and Research Center of Infectious Diseases Beijing Ditan HospitalCapital Medical UniversityBeijing 100015China Center for Drug Clinical Research Shanghai University of Traditional Chinese MedicineShanghai 201203China Beijing Co-CRO Medical Development Co. Ltd.Beijing 100711China State Key Laboratory for Infectious Disease Prevention and Control National Center for AIDS/STD Control and PreventionChinese Center for Disease Control and PreventionBeijing 102206China 不详

Background:Albuvirtide is a once-weekly injectable human immunodeficiency virus(HIV)-1 fusion *** present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral ***:We carried out a 48-week,randomized,controlled,open-label non-inferiority trial at 12 sites in *** on the World Health Organization(WHO)-recommended first-line treatment for>6 months with a plasma viral load>1000 copies/mL were enrolled and randomly assigned(1:1)to receive albuvirtide(once weekly)plus ritonavir-boosted lopinavir(ABT group)or the WHO-recommended second-line treatment(NRTI group).The primary endpoint was the proportion of patients with a plasma viral load below 50 copies/mL at 48 ***-inferiority was prespecified with a margin of 12%.Results:At the time of analysis,week 24 data were available for 83 and 92 patients,and week 48 data were available for 46 and 50 patients in the albuvirtide and NRTI groups,*** 48 weeks,80.4%of patients in the ABT group and 66.0%of those in the NRTI group had HIV-1 RNA levels below 50 copies/mL,meeting the criteria for *** the per-protocol population,the superiority of albuvirtide over NRTI was *** frequency of grade 3 to 4 adverse events was similar in the two groups;the most common adverse events were diarrhea,upper respiratory tract infections,and grade 3 to 4 increases in triglyceride *** function was significantly more impaired at 12 weeks in the patients of the NRTI group who received tenofovir disoproxil fumarate than in those of the ABT ***:The TALENT study is the first phase 3 trial of an injectable long-acting HIV *** interim analysis indicates that once-weekly albuvirtide in combination with ritonavir-boosted lopinavir is well tolerated and non-inferior to the WHO-recommended second-line regimen in patients with first-line treatme

关键词： HIV Fusion inhibitor Albuvirtide LPV/r Phase 3 clinical trial

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Immunity-and-matrix-regulatory cells enhance cartilage regeneration for meniscus injuries: a phase I dose-escalation trial

引用

Signal Transduction and Targeted Therapy 2023年第12期8卷 5873-5886页

作者： Liangjiang Huang Song Zhang jun wu Baojie Guo Tingting Gao Sayed Zulfiqar Ali Shah Bo Huang Yajie Li Bo zhu Jiaqi Fan Liu wang Yani Xiao Wenjing Liu Yao Tian Zhengyu Fang yingying Lv Lingfeng Xie Sheng Yao Gaotan Ke Xiaolin Huang ying Huang Yujuan Li yi Jia Zhongwen Li Guihai feng Yan Huo wei Li qi Zhou Jie Hao Baoyang Hu Hong Chen Department of Rehabilitation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina National Stem Cell Resource Center State Key Laboratory of Stem Cell and Reproductive BiologyInstitute of ZoologyInstitute for Stem Cell and RegenerationChinese Academy of SciencesBeijingChina Beijing Institute for Stem Cell and Regenerative Medicine BeijingChina Department of Radiology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina Stem Cell Research Center Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina Department of Orthopedics Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina University of Chinese Academy of Sciences BeijingChina Beijing Key Lab for Pre-clinical Safety Evaluation of Drugs National Center for Safety Evaluation of DrugsNational Institutes for Food and Drug ControlBeijingChina Beijing Zephyrm Biotechnologies Co. Ltd.BeijingChina

Immunity-and-matrix-regulatory cells(IMRCs)derived from human embryonic stem cells have unique abilities in modulating immunity and regulating the extracellular matrix,which could be mass-produced with stable biological *** resemblance to mesenchymal stem cells(MSCs)in terms of self-renew and tri-lineage differentiation,the ability of IMRCs to repair the meniscus and the underlying mechanism remains ***,we showed that IMRCs demonstrated stronger immunomodulatory and pro-regenerative potential than umbilical cord MSCs when stimulated by synovial fluid from patients with meniscus *** injection into the knees of rabbits with meniscal injury,IMRCs enhanced endogenous fibrocartilage *** the dose-escalating phase I clinical trial(NCT03839238)with eighteen patients recruited,we found that intra-articular IMRCs injection in patients was safe over 12 months ***,the effective results of magnetic resonance imaging(MRI)of meniscus repair and knee functional scores suggested that 5×107 cells are optimal for meniscus injury *** summary,we present the first report of a phase I clinical trial using IMRCs to treat meniscus *** results demonstrated that intra-articular injection of IMRCs is a safe and effective therapy by providing a permissive niche for cartilage regeneration.

关键词： meniscus injuries cartilage

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Diagnosis and Treatment of Cholangiocarcinoma: A Consensus from Surgical Specialists of China

引用

Journal of Huazhong University of Science and Technology(Medical Sciences) 2014年第4期34卷 469-475页

作者： Jian-qiang Cai Shou-wang Cai Wen-ming Cong Min-shan Chen Ping Chen Xiao-ping Chen Yan-ling Chen yi-fa Chen Chao-liu Dai qiang Huang Zhi-yong Huang Bo Jiang Bin Jiang Ke-wei Jiang Bo Li Zong-fangLi Li-jian Liang Bin Liu Hui-chun Liu Lian-xin Liu qing-guang Liu Rong Liu ying-bin Liu Jian-guo Lu Shi-chun Lu yi Lu yi-lei Mao Bin Mei jun Niu Bao-gang Peng Xiao qin Yu-dong qiu Guang-yi wang Yao-don wangg Zhi-ming wang Ren-hua Wan Ya-fu wu Bao-cai Xing feng Xia Ge-liang Xu Jia-mei Yang Xiao-fang Yu yong Zeng yong-yi Zeng Bi-xiang Zhang Bin-hao Zhang qi-yu Zhang Shui-jun Zhang Wan-guang Zhang yong-jie Zhang Zhi-wei Zhang Dong Zhou wei-ping Zhou Cancer Institute and Hospital Chinese Academy of Medical Sciences Chinese PLA General Hospital Eastern Hepatobiliary Surgery Hospital of Second Military Medical University Sun Yat-sen University Cancer Center Daping Hospital of Third Military Medical University Tongji Hospital Tongji Medical CollegeHuazhong University of Science and Technology Fujian Medical University Union Hospital Shengjing Hospital of China Medical University Anhui Provincial Hospital Hunan Provincial People’s Hospital Taihe Hospital Affiliated to Hubei University of Medicine Peking University People’s Hospital West China Hospital Sichuan University The Second Affiliated Hospital of Xi’an Jiao Tong University The First Affiliated Hospital Sun Yat-sen University First Affiliated Hospital of Kunming Medical University The First Affiliated Hospital of Bengbu Medical College The First Affiliated Hospital of Harbin Medical University The First Affiliated Hospital of Xi’an Jiao Tong University Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Tangdu Hospital of Fourth Military Medical University Peking Union Medical College Hospital qilu Hospital of Shandong University The First Affiliated Hospital of Guangxi Medical University Nanjing Drum Tower Hospital The First Affiliated Hospital of Jilin University Fujian Provincial Hospital Xiangya Hospital of Central South University The First Affiliated Hospital of Nanchang University Beijing Cancer Hospital Southwest Hospital of Third Military Medical University Shenzhen People’s Hospital The First Affiliated Hospital of Fujian Medical University The First Affiliated Hospital of Wenzhou Medical University The First Affiliated Hospital of Zhengzhou University Fujian Provincial Cancer Hospital

Cholangiocarcinoma refers to malignant tumors that develop in epithelial lining of biliary system, and it is divided into two categories according to tumor location, intrahepatic cholangiocarcinoma （ICC） and extrahepatic cholangiocarcinoma （ECC）. ICC occurs from the epithelial cells of the intrahepatic bile duct, its branches and interlobular biliary tree; and ECC is divided into hilar cholangiocarcinoma and distal cholangiocarcinoma by the circumscription at the confluence of cystic duct and the common hepatic duct.

关键词： A Consensus from Surgical Specialists of China Diagnosis and Treatment of Cholangiocarcinoma

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Timing analysis of the black hole candidate EXO 1846–031 with Insight-HXMT monitoring

引用

Research in Astronomy and Astrophysics 2021年第3期21卷 193-204页

作者： He-Xin Liu Yue Huang Guang-Cheng Xiao qing-Cui Bu Jin-Lu Qu Shu Zhang Shuang-Nan Zhang Shu-Mei Jia Fang-jun Lu Xiang Ma Lian Tao wei Zhang Li Chen Li-Ming Song Ti-Pei Li Yu-Peng Xu Xue-Lei Cao yong Chen Cong-Zhan Liu Ce Cai Zhi Chang Gang Chen Tian-Xiang Chen yi-Bao Chen Yu-Peng Chen wei Cui wei-wei Cui Jing-Kang Deng yong-wei Dong Yuan-Yuan Du Min-Xue Fu Guan-Hua Gao He Gao Min Gao Ming-Yu Ge Yu-Dong Gu Ju Guan Cheng-Cheng Guo Da-wei Han Jia Huo Lu-Hua Jiang wei-Chun Jiang Jing Jin yong-Jie Jin Ling-Da Kong Bing Li Cheng-Kui Li Gang Li Mao-Shun Li wei Li Xian Li Xiao-Bo Li Xu-Fang Li Yang-Guo Li Zheng-wei Li Xiao-Hua Liang Jing-Yuan Liao Bai-Sheng Liu Guo-qing Liu Hong-wei Liu Xiao-Jing Liu yi-Nong Liu Bo Lu Xue-feng Lu qi Luo Tao Luo Bin Meng yi Nang Jian-yin Nie Ge Ou Na Sai Ren-Cheng Shang Xin-ying Song Liang Sun ying Tan You-Li Tuo Chen wang Guo-feng wang Juan wang Ling-jun wang Weng-Shuai wang Yu-Sa wang Xiang-Yang Wen Bai-Yang wu Bo-Bing wu Mei wu Shuo Xiao Shao-Lin Xiong He Xu Jia-wei Yang Sheng Yang Yan-Ji Yang yi-jung Yang qi-Bin yi qian-qing yin Yuan You Ai-Mei Zhang Cheng-Mo Zhang Fan Zhang Hong-Mei Zhang Juan Zhang Tong Zhang Wan-Chang Zhang Wen-Zhao Zhang yi Zhang yi-Fei Zhang yong-Jie Zhang Yuan-Hang Zhang Yue Zhang Zhao Zhang Zhi Zhang Zi-Liang Zhang Hai-Sheng Zhao Xiao-Fan Zhao Shi-Jie Zheng Yao-Guang Zheng Deng-Ke Zhou Jian-feng Zhou Yu-Xuan zhu Ren-Lin zhuang Yue zhu Key Laboratory of Particle Astrophysics Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China University of Chinese Academy of Sciences Chinese Academy of SciencesBeijing 100049China Institut fur Astronomie und Astrophysik Kepler Center for Astro and Particle PhysicsEberhard Karls Universität72076 TubingenGermany Department of Astronomy Beijing Normal UniversityBeijing 100088China Department of Astronomy Tsinghua UniversityBeijing 100084China Department of Physics Tsinghua UniversityBeijing 100084China Department of Engineering Physics Tsinghua UniversityBeijing 100084China Key Laboratory of Space Astronomy and Technology National Astronomical ObservatoriesChinese Academy of SciencesBeijing 100101China College of Physics Sciences&Technology Hebei UniversityBaoding 071002Hebei ProvinceChina

We present the observational results from a detailed timing analysis of the black hole candidate EXO 1846-031 during its outburst in 2019 with the observations of Insight-HXMT,NICER and *** outburst can be classified roughly into four different ***-C quasi-periodic oscillations(QPOs)observed by NICER(about 0.1-6 Hz)and Insight-HXMT(about 0.7-8 Hz)are also reported in this ***,we study various physical quantities related to QPO *** QPO rms-frequency relationship in the energy band 1-10 keV indicates that there is a turning pointing in frequency around2 Hz,which is similar to that of GRS 1915+105.A possible hypothesis for the relationship above may be related to the inclination of the source,which may require a high inclination to explain *** relationships between QPO frequency and QPO rms,hardness,total fractional rms and count rate have also been found in other transient sources,which can indicate that the origin of type-C QPOs is non-thermal.

关键词： X-ray binaries black hole candidate QPO EXO 1846–031

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection:a randomized trial

引用

Signal Transduction and Targeted Therapy 2021年第10期6卷 3009-3018页

作者： jun Liu Dan-Dan Li wei Dong Yu-qi Liu Yang wu Da-Xuan Tang Fu-Chun Zhang Meng qiu qi Hua Jing-Yu He jun Li Bai Du Ting-Hai Du Lin-Lin Niu Xue-jun Jiang Bo Cui Jiang-Bin Chen Yang-Gan wang Hai-Rong wang qin Yu Jing He yi-Lin Mao Xiao-Fang Bin Yue Deng Yu-Dan Tian qing-Hua Han Da-Jin Liu Li-qin Duan Ming-jun Zhao Cui-ying Zhang Hai-ying Dai Ze-Hua Li ying Xiao You-Zhi Hu Xiao-Yu Huang Kun Xing Xin Jiang Chao-feng Liu Jing An feng-Chun Li Tao Tao Jin-Fa Jiang ying Yang Yao-Rong Dong Lei Zhang Guang Fu ying Li Shu-wei Huang Li-Ping Dou Lan-jun Sun ying-qiang Zhao Jie Li Yun Xia jun Liu Fan Liu Wen-Jin He ying Li Jian-Cong Tan Yang Lin Ya-Bin Zhou Jian-Fei Yang Guo-qing Ma Hui-jun Chen He-Ping Liu Zong-wu Liu Jian-Xiong Liu Xiao-Jia Luo Xiao-Hong Bin Ya-Nan Yu Hai-Xia Dang Bing Li Fei Teng wang-Min qiao Xiao-Long zhu Bing-wei Chen qi-Guang Chen Chun-Ti Shen yong-Yan wang Yun-Dai Chen Zhong wang Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijingChina Department of Cardiology Chinese PLA General HospitalBeijingChina Department of Cardiology Dongfang Hospital Affiliated to Beijing University of Chinese MedicineBeijingChina Department of Geratology Peking University Third HospitalBeijingChina Department of Cardiology Xuan Wu HospitalCapital Medical UniversityBeijingChina Department of Cardiology Guang'anmen HospitalChina Academy of Chinese Medical SciencesBeijingChina Department of Cardiology First Affiliated Hospital of Henan University of Chinese MedicineZhengzhouHenanChina Department of Cardiology Wuhan University Renmin HospitalWuhanHubeiChina Department of Cardiology Wuhan University Zhongnan HospitalWuhanHubeiChina Affiliated Zhongshan Hospital of Dalian University DalianLiaoningChina Department of Cardiology Second Affiliated Hospital to Hunan University of Chinese MedicineChangshaHunanChina Department of Cardiology First Affiliated Hospital to Changchun University of Chinese MedicineChangchunJilinChina Department of Cardiology First Affiliated Hospital to Shanxi Medical UniversityTaiyuanShanxiChina Department of Cardiology Affiliated Hospital of Shanxi University of Chinese MedicineXianyangShanxiChina Department of Cardiology Changsha Central HospitalChangshaHunanChina Department of Cardiology Hubei Provincial Hospital of Traditional Chinese MedicineWuhanHubeiChina Department of Cardiology Shanxi Provincial People's HospitalXi'anShanxiChina Department of Cardiology Shanxi Province Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of Cardiology Xi'an City Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of Cardiology Shanghai Tongji HospitalShanghaiChina Department of Cardiology Shanghai Municipal Hospital of Traditional Chinese MedicineShanghaiChina Department of Cardiology The First Hospital of ChangshaChangshaHunanChina Department of Cardiology Xinhua Hospi

It's a challenge for detecting the therapeutic targets of a polypharmacological drug from variations in the responsed networks in thedfferentiated populations with complex diseases,as stable coronary heart ***,in an adaptive,31-center,randomized,double-blind trial invoving 920 patients with moderate symptomatic stable angina treated by 14-day Danhong injection(DHI),a kind of polyphamacological drug with high quality control,or placebo(0.9%saline),with 76-day following-up,we firstly confrmed that DHl couldincrease the proportion of patients with clinically significant changes on angina-frequency assessed by Seattle Angina Questionnaire(ASAQ-AF220)(12.78%at Day 30,95%confidence interval[C]5.86-19.71%,P=0.0003,13.82%at Day 6C0,95%CI 6.82-20.82%,P=0.0001and 8.95%at Day 90,95%CI 2.06-15.85%,P=0.01).We also found that there were no significant differences in new-onset major vascularevents(P=0.8502)and serious adverse events(P=0.9105)between DHl and *** performing the RNA sequencing in 62 selectedpatients,we developed a systemic modular approach tp identfy differentilly expressed modules(DEMs)of DHI with the Z_(summay)valueless than 0 compared with the control group,calculated by weighted gene co-expression network analysis(WGCNA),and sketched out thebasic framework on a modular map with 25 functional modules targeted by ***,the effective therapeutic module(ETM),defined as the highest corelation value with the phenotype alteration(SAQ-AF,the change in SAQ-AF at Day 30 from baseline)calculatedby WGCNA,was identifed in the population with the best effect(ASAQ-AF240),which is related to anticoagulation and regulation ofcholesterol *** assessed the modular flexbility of this ETM using the global topological D value based on Euclidean distance,which is corelated with phenotype alteration(r^(2):0.8204,P=0.019)by linear *** study identified the ant-angina therapeuticmodule in the effective population treated by the multi-target

关键词： angina injection sketch

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Expression profile of microRNAs in gastrointestinal stromal tumors revealed by high throughput quantitative RT-PCR microarray

引用

World Journal of Gastroenterology 2015年第19期21卷 5843-5855页

作者： Han-Xing Tong Yu-Hong Zhou ying-yong Hou yong Zhang Yuan Huang Bin Xie Jiong-Yuan wang Quan Jiang jun-yi He Ye-Bo Shao wu-Mei Han Ruo-ying Tan jun zhu wei-qi Lu Department of General Surgery Zhongshan Hospital Fudan University Department of Oncology Zhongshan HospitalFudan University Department of Pathology Zhongshan HospitalFudan University The Center of Endoscopy Zhongshan HospitalFudan University Department of Surgery The Central Hospital of Zaozhuang Mining Group Biovue Technology Ltd

AIM: To investigate the microRNA(miRNA) expression profile in gastrointestinal stromal tumor(GIST) tissues that could serve as a novel diagnostic biomarker for GIST ***: We performed a quantitative real-time quantitative reverse transcriptase polymerase chain reaction assay to analyze the expression of 1888 miRNAs in a sample set that included 54 GIST tissue ***: We found that dysregulation of several miRNAs may be related to the malignant potential of GISTs. Six of these miRNAs, hsa-let-7c, miR-218,miR-488#, miR-4683, miR-34c-5p and miR-4773, were selected as the final list of biomarkers to separate the malignant GISTs(M group) from the benign GISTs(B group). In addition, MiR-29b-2#, hsa-let-7c, miR-891 b, miR-218, miR-204, miR-204-3p, miR-628-5p,miR-744, miR-29c#, miR-625 and miR-196 a were used to distinguish between the borderline(BO group) and M groups. There were 11 common miRNAs selected to separate the benign and borderline(BB) group from the M group, including hsa-let-7c, miR-218, miR-628-5p,miR-204-3p, miR-204, miR-891 b, miR-488#, miR-145,miR-891 a, miR-34c-5p and miR-196 ***: The identified miRNAs appear tobe novel biomarkers to distinguish malignant from benign GISTs, which may be helpful to understand the mechanisms of GIST oncogenesis and progression,and to further elucidate the characteristics of GIST subtypes.

关键词： Gastrointestinal stromal tumors microRNAs Microarray analysis Real-time polymerase chainreaction Diagnosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

引用

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： Jie wu Shu-wei Duan Hong-tao Yang Yue-yi Deng wei Li Ya-ni He Zhao-hui Ni yong-li Zhan Shan Lin Zhi-yong Guo jun zhu Jing-ai Fang Xu-sheng Liu Li-hua wang Rong wang Nian-song wang Xiao-hong Cheng Li-qun He Ping Luo Shi-ren Sun Ji-feng Sun Ai-ping yin Geng-ru Jiang Hong-yu Chen Wen-hu Liu Hong-li Lin Meng Liang Lu Ma Ming Chen Li-qun Song Jian Chen qing zhu Chang-ying Xing Yun Li Ji-ning Gao Rong-shan Li ying Li Hao Zhang ying Lu qiao-ling Zhou jun-zhou Fu qiang He Guang-yan Cai Xiang-mei Chen Department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China Department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina Department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China Department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China Department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China Department of Nephrology Tianjin Medical University General HospitalTianjin 300052China Department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China Department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina Department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina Department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China Department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina Department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China Department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(P<0.001)greater reduction in urine protein *** with the losartan potassium 100 mg group,the SYKFT plus losartan potassium 100 mg group had a 9.77%±2.52%(P=0.001)greater reduction in urine *** a superiority threshold of 15%,neither was statistically ***,serum creatinine and serum albumin from the baseline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

振动水翼低阶振型的阻尼特性试验研究

引用

机械工程学报 2022年第5期58卷 108-118页

作者：曾永顺齐鑫姚志峰王静竹王一伟王福军中国农业大学水利与土木工程学院北京100083 北京市供水管网系统安全与节能工程技术研究中心北京100083 中国科学院力学研究所流固耦合系统力学重点实验室北京100190

水力机械过流部件与环境流体相互作用产生的附加质量和阻尼效应,对其动力响应特性有显著影响。本研究重点测量了空气和水中振动水翼前四阶振型的阻尼特性参数。通过在水翼前缘嵌入一个压电片施加激励,采用激光测振仪和水翼尾缘的压电片... 详细信息

水力机械过流部件与环境流体相互作用产生的附加质量和阻尼效应,对其动力响应特性有显著影响。本研究重点测量了空气和水中振动水翼前四阶振型的阻尼特性参数。通过在水翼前缘嵌入一个压电片施加激励,采用激光测振仪和水翼尾缘的压电片同时获取振动响应信号并相互校准,构建了叶片式结构模态参数测试系统。将压电片信号作为基准信号,同步激光测振仪的多点响应信号,提出了一种单振型测量方法。重点分析了对数衰减法、希尔伯特变换法、共振放大法、半功率带宽法和圆圈拟合法五种常用的阻尼比识别方法。结果表明:五种阻尼比识别方法的精度和不确定度在同一量级,综合比较后认为,对于自由振动响应信号推荐采用对数衰减法,强迫振动响应信号则推荐采用半功率带宽法;空气和水中在同一振型条件下,水翼不同位置点的阻尼比基本保持不变,最大偏差为5.8%;相比空气环境,水中水翼各阶固有频率下降率在6.49%~26.73%之间,各阶模态对应的振型未见明显差异;水中振动水翼阻尼比变化趋势依赖于具体振型,其中,1阶弯曲、1阶扭转和1阶弯扭振型对应的阻尼比分别增大13.09%、8.61%和14.34%,但2阶弯曲振型对应的阻尼比则减小16.25%。

关键词：水力机械水翼阻尼识别方法阻尼比振型

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：